Serum CD166: A novel biomarker for predicting nasopharyngeal carcinoma response to radiotherapy
Metrics: PDF 1722 views | HTML 2718 views | ?
Huan Lin1,2,*, Ze-Tan Chen1,2,*, Xiao-Dong Zhu1,2,3, Ling Li1,2,3, Song Qu1,2,3, Wei Zhao1,2, Fang Su1,2, Jing-Ni Wei1,2, Zhong-Guo Liang1,2, Qi-Yan Mo1,2, Jiang-Bo Wu1,2 and Hui-Ling Meng1,2
1Department of Radiation Oncology, Affiliated Cancer Hospital of Guangxi Medical University and Cancer Institute of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, P.R. China
2Guangxi Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
3Key Laboratory of High-Incidence-Tumor Prevention and Treatment (Guangxi Medical University), Ministry of Education, Nanning, Guangxi 530021, P.R. China
*These authors have contributed equally to this work
Xiao-Dong Zhu, email: [email protected]
Keywords: nasopharyngeal carcinoma, radiosensitivity, radioresistance, biomarker, CD166/ALCAM
Received: October 26, 2016 Accepted: March 01, 2017 Published: March 21, 2017
The present study aimed to identify whether CD166 can be used as a biomarker for predicting the response of nasopharyngeal carcinoma (NPC) to radiotherapy. The serum concentration of CD166 in patients with NPC were detected by enzyme-linked immunosorbent assay. The secreted level of CD166 with radioresistant NPC was significantly higher than that with radiosensitive NPC. In vitro, the CD166 positive rate in the CNE2 cell membrane was significantly lower than that in the CNE2R cell membrane. The magnetic-activated cell sorting technology was used to obtain CNE-2R-CD166(+) and CNE-2R-CD166(–) cell lines. Then radiosensitivity, cell proliferation, and apoptosis were assessed using colony formation assay, cell counting kit 8 assay (CCK-8), and flow cytometry, respectively. The radiation sensitivity ratio was 1.28, indicating that the CNE2R-CD166(–) cells had a stronger radiation sensitivity. The result of CCK-8 assay indicated that the survival fraction of CNE2R-CD166(+) cells was significantly higher than that of CNE2R-CD166(–) cells. The apoptotic rate of CNE2R-CD166(+) cells was significantly lower than that of CNE2R-CD166(–) cells. Our data demonstrate that the secreted protein CD166 may be can used as a biomarker for predicting the response of NPC to radiotherapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.